Clearside Biomedical (CLSD) Downgraded by Zacks Investment Research to Hold

Clearside Biomedical stock has undergone multiple analysts rating changes in the recent past.  Clearside Biomedical Downgraded by Zacks Investment Research on 10/13/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.

Shares of Clearside Biomedical traded up $0.05 on Wednesday, reaching $5.65. 463220 shares of the stock traded hands, compared to its average volume of 510216. Shares of Clearside Biomedical were trading at $5.65 on Wednesday. The firm’s 50 day moving average is $6.05 and its 200 day moving average is $4.15.Clearside Biomedical has a 12 month low of $5.44 and a 12 month high of $7.73. While on yearly highs and lows, Clearside Biomedical’s today has traded high as $5.72 and has touched $5.44 on the downward trend. See More Analyst Rating at: RATING

Clearside Biomedical Earnings and What to expect: 

Clearside Biomedical last issued its earnings results on August 9th, 2021. The reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. The company earned $0.78 million during the quarter, compared to analysts’ expectations of $0.74 million. Clearside Biomedical has generated ($0.39) earnings per share over the last year (($0.43) diluted earnings per share). Earnings for Clearside Biomedical are expected to decrease in the coming year, from ($0.22) to ($0.35) per share. Clearside Biomedical has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, November 9th, 2021 based off prior year’s report dates.

Earnings for Clearside Biomedical are expected to decrease in the coming year, from ($0.22) to ($0.35) per share. The P/E ratio of Clearside Biomedical is -13.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Clearside Biomedical is -13.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Clearside Biomedical has a P/B Ratio of 31.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Clearside Biomedical (CLSD) Moving Average Technical Analysis

5 day Moving Average is $5.30 And 5 day price change is $0.74 (15.07%)  with average volume for 5 day average is 450,320. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $5.91 and 20 day price change is -$0.92 (-14.00%) and average 20 day moving volume is 514,810. 50 day moving average is $6.05  and 50 day price change is $0.52 ( 10.14%)  and with average volume for 50 days is : 550,888. 200 day moving average is $4.15  and 200 day price change is $3.53 (166.51%)  and with average volume for 200 days is : 1,407,621.

Other owners latest trading in Clearside Biomedical :

  • On 10/7/2021 shares held by Newman Dignan & Sheerar Inc. were 21,523 which equates to market value of $0.13M and appx 0.00% owners of Clearside Biomedical
  • On 8/25/2021 shares held by Marshall Wace LLP were 230,441 which equates to market value of $1.12M and appx 0.00% owners of Clearside Biomedical
  • On 8/23/2021 shares held by Morgan Stanley were 285,861 which equates to market value of $1.39M and appx 0.00% owners of Clearside Biomedical
  • In total Institutional ownership equates to Institutional Ownership Percentage: 33.06% for Clearside Biomedical

See More Analyst Rating at: RATING